𝔖 Bobbio Scriptorium
✦   LIBER   ✦

6010 A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial

✍ Scribed by Hoff, P.; Clarke, S.; Cunningham, D.; Van Cutsem, E.; Moore, M.; Schmoll, H.J.; Tabernero, J.; Mueller, B.; De Gramont, A.


Book ID
123017328
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
48 KB
Volume
7
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.